Johnson & JohnsonvsVeracyte

JNJ and VCYT stock compared: price, dividend, valuation and results, from SEC filings.

Johnson & Johnson (JNJ) has a market value of $644B and Veracyte (VCYT) $2.0B. Over the last year, with dividends, JNJ moved +36.6% and VCYT -35.4%. The P/E is 40.0 for JNJ and 15.7 for VCYT. Dividend yield: JNJ 1.98%, VCYT none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$644B

    VCYT$2.0B

    JNJ is 324 times VCYT

  • Revenue, 12 months

    JNJ$99.3B

    VCYT$582M

    JNJ is 171 times VCYT

  • Net income, 12 months

    JNJ$16.1B

    VCYT$127M

    JNJ is 127 times VCYT

  • Operating margin

    JNJ–

    VCYT17.1%

  • ROIC

    JNJ12.4%

    VCYT5.8%

    6.6 points apart

  • P/E

    JNJ40.0

    VCYT15.7

    JNJ is 2.5 times VCYT

  • Dividend yield

    JNJ2.0%

    VCYT0.0%

    2.0 points apart

  • 5-year return

    JNJ+89.1%

    VCYT-44.9%

    134.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+89.1%

VCYT-44.9%

5010015020020222023202420252026
Returns by period
PeriodJNJWith dividendsVCYTWith dividends
1 year since November 18, 2025+36.6%Price +33.6%-35.4%Price -35.4%
3 years since November 17, 2023+94.2%+24.8% a yearPrice +78.3%-0.8%-0.3% a yearPrice -0.8%
5 years since November 18, 2021+89.1%+13.6% a yearPrice +64.5%-44.9%-11.2% a yearPrice -44.9%
10 years since November 21, 2016+202.7%+11.7% a yearPrice +132.3%+227.3%+12.6% a yearPrice +227.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonVCYTVeracyte

Valuation

JNJVCYT
Valuation
Price$267.14$25.04
Market value$644B$2.0B
Enterprise value (EV)$671B$1.8B
P/E40.015.7
P/E, 5-year median21.9–
P/B7.91.4
EV/EBIT37.818.0
Free cash flow yield3.2%8.1%

Results and growth

JNJVCYT
Results and growth
Revenue, 12 months$99.3B$582M
Net income, 12 months$16.1B$127M
Free cash flow, 12 months$20.6B$162M
Earnings per share, 12 months$6.59$1.54
Revenue growth, year on year6.1%16.0%
Revenue growth a year, past+2.7%over 5 years+34.5%over 5 years
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJVCYT
Margins and returns on capital
Gross margin67.6%72.0%
Operating margin–17.1%
Net margin16.2%21.8%
ROIC12.4%5.8%
ROE19.7%9.4%

Balance sheet

JNJVCYT
Balance sheet
Cash$17.2B$200M
Total debt$44.7B$41M
Net debt / EBITDA1.1-1.7
Interest cover18.0×–

Dividends and buybacks

JNJVCYT
Dividends and buybacks
Dividend yield2.0%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or VCYT

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Veracyte?

By market value, Johnson & Johnson ($644B) is about 323.6 times Veracyte ($2.0B), at today's prices.

How did JNJ and VCYT stock do over the last 10 years?

Since November 21, 2016, JNJ's price moved +132.3% and VCYT's +227.3%. With dividends: JNJ +202.7% (+11.7% a year), VCYT +227.3% (+12.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or VCYT?

The dividend yield at today's price is 1.98% for Johnson & Johnson and none for Veracyte. Over the last twelve months they paid $5.28 and – per share.

What is the P/E of JNJ and VCYT?

At today's price, the P/E is 40.0 for JNJ and 15.7 for VCYT. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Johnson & Johnson or Veracyte?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 21.8% for Veracyte, and the operating margin – and 17.1%. Revenue was $99.3B and $582M.

Which is the better investment, Johnson & Johnson or Veracyte?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.